welcome to DuchenneXchange
- a positively charged Duchenne muscular dystrophy community.- join today!
- login
First Patient Dosed in Phase II Clinical Trial in Duchenne Muscular Dystrophy
Antisense Therapeutics today announced dosing of the first patient in a Phase II clinical trial of its immunomodulatory therapy, ATL1102, in patients with Duchenne Muscular Dystrophy (DMD).
Commencement of the trial represents an important development milestone for the Company and for patients seeking better and safer treatments.
ATL1102 is an inhibitor of CD49d expression on certain immune cells (T cells). DMD patients who have a greater number of T cells with high levels of CD49d on their surface have more severe and rapid disease progression.
rareRelated
-
Summit announces PhaseOut DMD did not meet primary endpointSummit Therapeutics announced today that...
-
The PTC124 (Ataluren) Clinical Trial for Duchenne Muscular Dystrophy: Exploration of the Experiences of Parents, Cli...The purpose of this study is to describe...
-
Clay Matthews Supports Duchenne Muscular Dystrophy and First Approved Treatmenthttps://www.youtube.com/watch?v=WPu5pGEF...
-
PTC Therapeutics Announces Positive Data from its Translarna™ Phase II Clinical Trial in Children as Young as Two ...PTC Therapeutics, Inc. today announced t...
-
New therapeutic approaches: I.9 Treatment of Duchenne muscular dystrophy: current efforts, bottlenecks and future pr...In the last decade a number of therapeut...
-
CoQ10 and Prednisone in Non-Ambulatory DMDThis study will help determine if CoQ10 ...
-
BioMarin snags cash as Sarepta skips Duchenne patent battleSarepta Therapeutics Inc. agreed to pay...